• Corpus ID: 147636386

Using TUDCA to treat Alzheimer's disease after pathology onset in APP/PS1 mice

@inproceedings{Dionsio2014UsingTT,
  title={Using TUDCA to treat Alzheimer's disease after pathology onset in APP/PS1 mice},
  author={Pedro El{\'o}i Antunes Dion{\'i}sio},
  year={2014}
}
Tese de mestrado, Ciencias Biofarmaceuticas, Universidade de Lisboa, Faculdade de Farmacia, 2014 

References

SHOWING 1-10 OF 282 REFERENCES

Alzheimer's Disease Is a Synaptic Failure

Mounting evidence suggests that this syndrome begins with subtle alterations of hippocampal synaptic efficacy prior to frank neuronal degeneration, and that the synaptic dysfunction is caused by diffusible oligomeric assemblies of the amyloid β protein.

Elevated β-secretase expression and enzymatic activity detected in sporadic Alzheimer disease

Elevated β-secretase expression and enzymatic activity detected in sporadic Alzheimer disease and its role in Alzheimer's disease is still unclear.

Single App knock-in mouse models of Alzheimer's disease

Experimental studies of Alzheimer's disease have largely depended on transgenic mice overexpressing amyloid precursor protein (APP). These mice, however, suffer from artificial phenotypes because, in

Immunotherapy for Alzheimer’s disease: hoops and hurdles

  • C. Lemere
  • Biology
    Molecular Neurodegeneration
  • 2013
Efforts are now underway to treat individuals at risk for AD prior to or in the earliest stages of cognitive decline with the hope of preventing or delaying the onset of the disease.

Reducing Endogenous Tau Ameliorates Amyloid ß-Induced Deficits in an Alzheimer's Disease Mouse Model

Reducing endogenous tau levels prevented behavioral deficits in transgenic mice expressing human amyloid precursor protein, without altering their high Aβ levels, and protected both transgenic and nontransgenic mice against excitotoxicity.

Evidence that glycogen synthase kinase‐3 isoforms have distinct substrate preference in the brain

J. Neurochem. (2010) 115, 974–983.

Frontiers in Alzheimer’s disease therapeutics

Novel AD therapeutics that are currently being explored are summarized, and mechanisms of action of specific drugs within the context of current knowledge of AD pathologic pathways are summarized.

Oxidative stress in Alzheimer disease: A possibility for prevention

...